News

iQure Pharma Secures $4M Funding – Advancing Phase 1 Clinical Trial for iQ-007

Princeton, NJ, January 07, 2025 ─ iQure Pharma Inc. (iQure), a biotechnology company focused on the development of novel therapies for...

Jan 7

Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study

Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...

Mar 19, 2024

iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain

Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...

Jan 23, 2024

iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024

Princeton, NJ, December 22, 2023 ─ iQure Pharma Inc. (iQure), a U.S.-based pre-clinical drug discovery company focusing on central...

Dec 22, 2023

iQure Pharma Announces Impressive Second Close of Oversubscribed Series A Financing

Princeton, NJ, 28 November, 2023 ─ iQure Pharma Inc, (iQure) a trailblazing pre-clinical drug discovery company focusing on central...

Nov 28, 2023

iQure Pharma Secures Funding from Ventura BioMed Investors and OKG Capital

Princeton, NJ, October 11, 2023 ─ iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain...

Oct 11, 2023

iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for...

Jul 5, 2023

iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023

Princeton, NJ, December 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, is attending the 41st Annual J.P. Morgan...

Dec 14, 2022

iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to...

Sep 18, 2022

iQure Pharma Secures $600K in Commitments in Early Closing to Research Neuropathic Pain Therapies

Keiretsu Forum and Business Angel Investors Provide Funding to Support Research into Neuropathic Pain Compounds iQ-007 and iQ-008...

Aug 30, 2022

iQure Pharma Targets Future with New Board Appointments

Life Sciences industry experts Michael D. Webb and Brian Cain bring extensive expertise in strategic pharmaceutical growth DELAWARE,...

Apr 7, 2022

iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum

DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond...

Mar 1, 2022

Company signed Agreement with University of Arizona for non-opioid treatment of post-operative pain

Delaware – February 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of novel therapeutics in the area of pain...

Feb 16, 2021

iQure Pharma Inc. Secures Private Investment of $100,000

Delaware – September 2020, iQure Pharma Inc. (iQure), a company dedicated to preclinical and early clinical development of new...

Sep 14, 2020

iQure Pharma Inc. Secures Additional Investment of $50,000

Delaware – May, 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of new therapeutics, recently...

May 25, 2020

Chairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January

Chairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January

Dec 16, 2019

JPM Week

No Abuse